-
Overall Management of
#Individualizedtreatment for a Patient with Advanced#NSCLC by Shaozhong He in#BJSTR https://biomedres.us/fulltexts/BJSTR.MS.ID.003264.php … Follow on blogger : https://biomedres01.blogspot.com Like our pins on :: https://pinterest.com/biomedres/ pic.twitter.com/UPHmYiYo4s
-
Much needed new guidelines published to help doctors know how long to monitor
#NSCLC and#SCLC patients for post-treatment recurrence. Read the study's recommendations here:https://lcrf.org/1is -
#NSCLC is highly heterogeneous, with various driver mutations. Genetic testing can help identify patients who may benefit from targeted therapy. -
Kong et al. find that cell surface molecule
#CD44 promotes PD-L1 expression and establish CD44 as a key positive regulator of PD-L1 expression in#TNBC and#NSCLC.@mcgillu@McGillGCRC http://bit.ly/31tTtCX pic.twitter.com/IV9b0D5HWM
-
Lorlatinib is an important drug for relapsed ALK+
#NSCLC. Am hoping there will be constructive dialogue between NICE and Pfizer to allow an agreement on price. https://twitter.com/cr_uk/status/1225035350764138498 …
-
Do you have lung cancer? Speak to your doctor about what kind of
#lungcancer you have and if you could be eligible for the NRG Oncology LU003#clinical trial: http://bit.ly/NRG-LU003#NCORP#Cancer#Research#LSCM#NRGCares#NSCLC@IASLCpic.twitter.com/apkZfJVTHv
-
We believe that better health and a brighter future is achieved through collaboration. Hear from Dr.
@christine_lovly on the importance of teamwork in addressing the needs of people living with ALK+#NSCLC.#lcsmpic.twitter.com/RFYX9uBZ6hHow to work together to address the needs of the ALK+ NSCLC community? -
The application, which was based on final progression-free survival findings from the phase III CheckMate-227 trial, was originally filed in 2018 as a first-line treatment for patients with
#NSCLC who have tumor mutational burden ≥10 mutations/megabase http://ow.ly/iXeh50ycyFH -
Investigators hope selpercatinib, a highly selective RET inhibitor, will demonstrate potential as a new standard of care for patients with advanced or metastatic treatment-naïve RET fusion–positive
#NSCLC in the phase III LIBRETTO-431 trial@geoff_oxnard http://ow.ly/p4mx50ydGgQ -
Today is
#WorldCancerDay
. Our aiForward program helps scientists to harness the power of #AI in pathological and histological image analysis. Learn how Liesbeth Hondelink leverages our aiForward program for non-smell-cell lung cancer research: https://bit.ly/31g9QDi#NSCLC -
#Radiomics of FDG PET/CT images predicts severe immune-related adverse events in patients with#NSCLC https://doi.org/10.1148/ryai.2019190063 …@MoffittNewspic.twitter.com/KZTu0V5DaQ
-
Therapy for stage IV
#NSCLC without driver alterations:@ASCO and@CancerCare_ON joint guideline update:https://ascopubs.org/doi/full/10.1200/JCO.19.03022 … -
Opening 2020: IMP-MEL a phase 1/2 trial looking at whether a new drug works best alone or in combination in
#melanoma and#NSCLC@OxfordOncology#worldcancerday
pic.twitter.com/RSC8Cx8vWz
-
Publication in
@oncogenejournal | Dual disruption of aldehyde dehydrogenases 1 and 3 enhances chemosensitivity in non-small cell lung cancer.#NSCLC https://go.nature.com/36UTu4f -
Bristol-Myers Squibb has withdrawn its application in the European Union for the frontline combination of nivolumab and ipilimumab as a treatment for patients with advanced
#NSCLC#lcsm http://ow.ly/O0I250ycyEH -
Industry | Bristol-Myers Squibb withdraws European application of Opdivo plus Yervoy for the first-line treatment of advanced non-small cell lung cancer.
#NSCLC@bmsnewshttps://bwnews.pr/37YzRt6 -
One Year with a Stage IV Lung Cancer diagnosis and going strong. Thank goodness for prayer, positivity, research and amazing medicine. If you have lungs, you can get lung cancer! Love you
@dcwilson17#wilsonsvillage#alkpositive#nsclc@LungCancerFaces@GO2Foundation@LUNGevitypic.twitter.com/vUdGavb6bP
-
NICE Recommends Against Frontline Osimertinib in EGFR-Mutant
#NSCLC#lcsm#lcamhttp://ow.ly/9nmM50y8uQu -
Despite multiple biomarker-driven advances in Precision Medicine, NSCLC is one of the cancers in which the obstacles in diagnostic testing are severely impeding progress. Here's what we're doing to change that this
#WorldCancerDay
https://lnkd.in/ezaZDGe @uicc#NSCLC pic.twitter.com/t46UIZN4NE
-
.
@JackieFen1 presents findings from the patient experience study on concurrent chemo-radiation for stage III#NSCLC#BTOG20pic.twitter.com/g5vI529Tts
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.